Holen Sie sich die Stockscreener-App
0.6898
8.05%
0.0514
Handel nachbörslich:
.69
0.0002
+0.03%
Seres Therapeutics Inc Aktie (MCRB) Neueste Nachrichten
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2024 Earnings Call Transcript - Insider Monkey
Seres Therapeutics Advances SER-155 Program with FDA Support - TipRanks
Seres Therapeutics Inc (MCRB) Q4 2024 Earnings Call Highlights: Financial Improvements and ... - Yahoo Finance
Seres Therapeutics Inc (MCRB) Q4 2024 Earnings Call Highlights: Financial Improvements and Strategic Developments - GuruFocus.com
Seres Therapeutics Earnings Call: Progress Amid Uncertainty - TipRanks
Seres Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Evaluating MCRB’s financial ratios for a profitable investment - US Post News
Seres Therapeutics, Inc. SEC 10-K Report - TradingView
Earnings call transcript: Seres Therapeutics Q4 2024 financial results disappoint - Investing.com India
Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - The Manila Times
Seres Therapeutics Receives FDA Feedback Supporting SER-155 Study Plans for Bloodstream Infection Reduction in Allogeneic Hematopoietic Stem Cell Transplant Patients - Nasdaq
Seres Therapeutics Breakthrough Drug Cuts Infection Risk by 77% in Stem Cell Transplants - StockTitan
Seres Therapeutics Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
StockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to “Hold” - Defense World
Seres Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Seres Therapeutics (NASDAQ: MCRB) Stock Gains Momentum Ahead of Q4 Earnings - DRP Journal
Seres Therapeutics (MCRB) Expected to Announce Earnings on Thursday - Defense World
Microbiome Disease Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 140+ Companies and 180+ Therapies | DelveInsight - GlobeNewswire Inc.
Seres Therapeutics to Announce Fourth Quarter and Full Year - GlobeNewswire
Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025 - The Manila Times
When Will Seres Therapeutics Reveal Its 2024 Financial Performance? - StockTitan
FDA supports Seres Therapeutics’ study endpoint - Investing.com India
Seres Therapeutics receives feedback from FDA on SER-155 development approach - TipRanks
Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach - The Manila Times
FDA supports Seres Therapeutics' study endpoint - Investing.com
FDA supports Seres Therapeutics’ study endpoint By Investing.com - Investing.com Australia
Seres Therapeutics Receives Feedback From FDA on SER-155 - GlobeNewswire
Can Seres' SER-155 Reduce Post-Transplant Infections by 77%? FDA Backs Key Trial Endpoint - StockTitan
Seres Therapeutics (MCRB) Expected to Announce Earnings on Tuesday - Defense World
5 Best Microbiome Companies (March 2025) - Securities.io
Seres Therapeutics (MCRB) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Seres Therapeutics (NASDAQ:MCRB) Downgraded to "Sell" Rating by StockNews.com - MarketBeat
Seres Therapeutics, Inc.'s (NASDAQ:MCRB) market cap dropped US$15m last week; individual investors who hold 50% were hit as were institutions - Simply Wall St
Seres Therapeutics, Inc. Receives Feedback from Fda on Ser-155 Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct) Development Approach - Marketscreener.com
Seres Therapeutics Announces CMO Resignation in March 2025 - TipRanks
Investor Network: Seres Therapeutics Inc to Host Earnings Call - ACCESS Newswire
Seres Therapeutics (NASDAQ:MCRB) Downgraded by StockNews.com to “Sell” - Defense World
Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Purchased by Vontobel Holding Ltd. - MarketBeat
Seres Therapeutics executive sells shares worth $3,579 By Investing.com - Investing.com Nigeria
Seres Therapeutics officer sells $3,203 in stock By Investing.com - Investing.com South Africa
Seres Therapeutics, Inc. (NASDAQ:MCRB) CEO Eric D. Shaff Sells 12,726 Shares - MarketBeat
Seres Therapeutics CEO Eric Shaff sells $10,314 in stock - Investing.com India
Seres Therapeutics EVP sells $2,704 in stock By Investing.com - Investing.com South Africa
Seres Therapeutics CEO Eric Shaff sells $10,314 in stock By Investing.com - Investing.com South Africa
Seres Therapeutics exec Thomas Desrosier sells $3,485 in stock - Investing.com
Seres Therapeutics executive sells shares worth $3,579 - Investing.com
Seres Therapeutics EVP sells $2,704 in stock - Investing.com
Seres Therapeutics officer sells $3,203 in stock - Investing.com
Seres Therapeutics (NASDAQ:MCRB) Rating Increased to Hold at StockNews.com - MarketBeat
Seres Therapeutics (NASDAQ:MCRB) Stock Crosses Below 50-Day Moving AverageWhat's Next? - MarketBeat
Seres Therapeutics (NASDAQ:MCRB) Upgraded at StockNews.com - Defense World
Seres Therapeutics Inc (NASDAQ: MCRB) Stock Jumped 6.76% Over A Month – Is There Any Hope Of A Gain? - Marketing Sentinel
Janney Montgomery Scott LLC Lowers Stock Holdings in Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):